Table 2.
Effect sizes for ADAS-Cog versions at 12 and 24 months with and without amyloid imaging enrichment
| ES | 95% CI | Δμ | σ | n | ES | 95% CI | Δμ | σ | n | |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||
| Month 12 | Month 24 | |||||||||
|
|
||||||||||
| No SUVR enrichment | ||||||||||
|
|
||||||||||
| ADAS-Cog11 | 0.69 | 0.59–0.80 | 4.4 | 6.4 | 258 | 1.04 | 0.92–1.19 | 9.4 | 9 | 162 |
| ADAS-Cog12 | 0.73 | 0.62–0.84 | 4.7 | 6.5 | 249 | 1.13 | 1.00–1.29 | 9.5 | 8.4 | 150 |
| ADAS-Cog13 | 0.74 | 0.63–0.85 | 5.1 | 6.9 | 249 | 1.14 | 1.01–1.30 | 10.3 | 9.1 | 148 |
|
|
||||||||||
| SUVR ≥ 1.1 | ||||||||||
|
|
||||||||||
| ADAS-Cog11 | 0.78 | 0.59–1.01 | 4.8 | 6.1 | 91 | 1 | 0.67–1.57 | 8.4 | 8.4 | 24 |
| ADAS-Cog12 | 0.79 | 0.59–1.03 | 5.1 | 6.4 | 89 | 1.02 | 0.73–1.54 | 8.9 | 8.7 | 26 |
| ADAS-Cog13 | 0.84 | 0.64–1.09 | 5.7 | 6.7 | 89 | 1.07 | 0.78–1.56 | 10.1 | 9.5 | 24 |
|
|
||||||||||
| SUVR ≥ 1.3 | ||||||||||
|
|
||||||||||
| ADAS-Cog11 | 0.8 | 0.59–1.05 | 4.9 | 6.2 | 76 | 1.17 | 0.80–1.87 | 9.7 | 8.3 | 20 |
| ADAS-Cog12 | 0.83 | 0.62–1.09 | 5.2 | 6.3 | 74 | 1.15 | 0.82–1.75 | 10.1 | 8.8 | 22 |
| ADAS-Cog13 | 0.88 | 0.65–1.16 | 5.9 | 6.7 | 74 | 1.2 | 0.87–1.83 | 11.5 | 9.6 | 20 |
|
|
||||||||||
| SUVR ≥ 1.4 | ||||||||||
|
|
||||||||||
| ADAS-Cog11 | 0.77 | 0.55–1.06 | 5 | 6.4 | 58 | 1.2 | 0.73–2.18 | 11 | 9.2 | 15 |
| ADAS-Cog12 | 0.88 | 0.66–1.16 | 5.5 | 6.3 | 56 | 1.22 | 0.78–2.12 | 11.8 | 9.7 | 16 |
| ADAS-Cog13 | 0.96 | 0.74–1.26 | 6.3 | 6.6 | 56 | 1.21 | 0.80–2.03 | 12.9 | 10.7 | 15 |
Caption: ADAS-Cog = Alzheimer's Disease Assessment Scale-Cognitive Subscale, ES = effect size, CI = confidence interval, Δμ = mean change in ADAS-Cog, σ = standard deviation, n=sample size, SUVR = standardized uptake value ratio.